BonyPid is a combined drug and medical device product, which combines bone filler and a substantial antibiotic release platform.
The study has shown BonyPid’s positive effect in bone recovery processes, following its early implantation onto the bone void fractures performed in the first surgical procedure.
The trial included 16 males and females, aged between 18 and70, who were implanted with BonyPid in the first surgical procedure.
PolyPid CTO Noam Emanuel said the preliminary results demonstrated that BonyPid reduced or prevented bone infection and facilitated bone recovery.
”In addition, BonyPid™ enabled one surgical procedure and immediate closure of the open wound in most cases," Emanuel added.